Robert Fuhlbrigge
Concepts (504)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin | 23 | 2025 | 755 | 2.420 |
Why?
| | Arthritis, Juvenile | 9 | 2022 | 56 | 1.670 |
Why?
| | Vaccinia virus | 7 | 2017 | 34 | 1.280 |
Why?
| | E-Selectin | 15 | 2019 | 61 | 1.110 |
Why?
| | Rheumatic Diseases | 3 | 2021 | 97 | 1.060 |
Why?
| | Vaccinia | 4 | 2017 | 20 | 0.930 |
Why?
| | CD8-Positive T-Lymphocytes | 8 | 2025 | 917 | 0.850 |
Why?
| | Membrane Glycoproteins | 13 | 2007 | 496 | 0.760 |
Why?
| | Cell Adhesion | 14 | 2015 | 455 | 0.730 |
Why?
| | Blotting, Western | 7 | 2015 | 1187 | 0.720 |
Why?
| | Immunologic Surveillance | 4 | 2011 | 25 | 0.690 |
Why?
| | T-Lymphocytes | 13 | 2019 | 1982 | 0.630 |
Why?
| | Rheumatology | 1 | 2021 | 133 | 0.620 |
Why?
| | Immunologic Memory | 8 | 2025 | 366 | 0.600 |
Why?
| | Selectins | 5 | 2015 | 8 | 0.600 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 383 | 0.570 |
Why?
| | Immune System | 3 | 2011 | 179 | 0.560 |
Why?
| | Skin Diseases | 3 | 2009 | 149 | 0.550 |
Why?
| | Scleroderma, Localized | 4 | 2024 | 11 | 0.540 |
Why?
| | Down Syndrome | 2 | 2021 | 534 | 0.520 |
Why?
| | Skin Diseases, Infectious | 1 | 2017 | 13 | 0.520 |
Why?
| | Hemorrhage | 2 | 2023 | 809 | 0.510 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2020 | 389 | 0.500 |
Why?
| | Receptors, Lymphocyte Homing | 5 | 2007 | 15 | 0.490 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2017 | 253 | 0.490 |
Why?
| | Cell Adhesion Molecules | 3 | 2007 | 178 | 0.480 |
Why?
| | Antirheumatic Agents | 4 | 2022 | 304 | 0.460 |
Why?
| | Leukocytes | 6 | 2006 | 295 | 0.430 |
Why?
| | Cell Movement | 16 | 2017 | 965 | 0.430 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 57 | 0.430 |
Why?
| | Intercellular Adhesion Molecule-1 | 4 | 2019 | 138 | 0.430 |
Why?
| | Lung Diseases | 1 | 2021 | 787 | 0.420 |
Why?
| | Mechanical Phenomena | 1 | 2015 | 80 | 0.420 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2025 | 264 | 0.380 |
Why?
| | Dendritic Cells | 8 | 2016 | 499 | 0.380 |
Why?
| | P-Selectin | 10 | 2012 | 28 | 0.370 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 81 | 0.360 |
Why?
| | Scleroderma, Systemic | 3 | 2024 | 123 | 0.350 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 5 | 2012 | 45 | 0.350 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1519 | 0.340 |
Why?
| | Animals | 48 | 2025 | 38058 | 0.340 |
Why?
| | Models, Immunological | 4 | 2012 | 100 | 0.330 |
Why?
| | T-Lymphocyte Subsets | 5 | 2017 | 415 | 0.320 |
Why?
| | Leukosialin | 3 | 2011 | 12 | 0.320 |
Why?
| | Child | 29 | 2024 | 22633 | 0.310 |
Why?
| | L-Selectin | 7 | 2000 | 27 | 0.310 |
Why?
| | Systemic Vasculitis | 1 | 2009 | 2 | 0.310 |
Why?
| | Mice, Knockout | 12 | 2025 | 3121 | 0.300 |
Why?
| | Mice | 32 | 2025 | 18339 | 0.280 |
Why?
| | Antigens, Neoplasm | 9 | 2007 | 271 | 0.280 |
Why?
| | Skin Neoplasms | 4 | 2012 | 847 | 0.270 |
Why?
| | Blood Vessels | 1 | 2009 | 171 | 0.270 |
Why?
| | Th17 Cells | 2 | 2020 | 101 | 0.270 |
Why?
| | Cricetinae | 8 | 2015 | 303 | 0.270 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2015 | 177 | 0.270 |
Why?
| | Humans | 76 | 2025 | 144759 | 0.270 |
Why?
| | Antibodies, Viral | 1 | 2012 | 672 | 0.260 |
Why?
| | Mice, Inbred C57BL | 16 | 2025 | 5992 | 0.260 |
Why?
| | Comparative Effectiveness Research | 2 | 2019 | 170 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 1217 | 0.260 |
Why?
| | Melanoma | 3 | 2012 | 761 | 0.260 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 154 | 0.250 |
Why?
| | CHO Cells | 6 | 2015 | 171 | 0.250 |
Why?
| | Chemokines, CC | 3 | 2004 | 32 | 0.250 |
Why?
| | Immunity, Innate | 5 | 2012 | 846 | 0.250 |
Why?
| | Interleukin-1 | 7 | 1989 | 961 | 0.250 |
Why?
| | Lymphocyte Activation | 5 | 2010 | 1126 | 0.230 |
Why?
| | Monocytes | 3 | 2005 | 538 | 0.230 |
Why?
| | Biological Assay | 1 | 2006 | 128 | 0.220 |
Why?
| | Chemotaxis, Leukocyte | 4 | 2013 | 113 | 0.220 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 14 | 0.210 |
Why?
| | Synovial Membrane | 2 | 2024 | 124 | 0.210 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 124 | 0.200 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 78 | 0.200 |
Why?
| | Methotrexate | 4 | 2019 | 240 | 0.200 |
Why?
| | Arthritis, Rheumatoid | 2 | 2024 | 1169 | 0.200 |
Why?
| | Microscopic Polyangiitis | 1 | 2023 | 13 | 0.200 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 8 | 2007 | 100 | 0.200 |
Why?
| | Glucocorticoids | 3 | 2019 | 535 | 0.200 |
Why?
| | Churg-Strauss Syndrome | 1 | 2023 | 27 | 0.200 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2023 | 24 | 0.200 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2023 | 46 | 0.200 |
Why?
| | Thymus Gland | 1 | 2004 | 311 | 0.190 |
Why?
| | Granuloma | 1 | 2023 | 96 | 0.190 |
Why?
| | Myositis | 1 | 2023 | 57 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 479 | 0.190 |
Why?
| | Spondylarthropathies | 1 | 2022 | 5 | 0.180 |
Why?
| | Consensus | 4 | 2024 | 488 | 0.180 |
Why?
| | Cricetulus | 3 | 2015 | 118 | 0.180 |
Why?
| | Keratinocytes | 3 | 2016 | 248 | 0.180 |
Why?
| | Gene Expression Regulation | 4 | 2015 | 2608 | 0.180 |
Why?
| | Adaptive Immunity | 2 | 2020 | 169 | 0.170 |
Why?
| | Spondylitis, Ankylosing | 1 | 2022 | 43 | 0.170 |
Why?
| | Spondylarthritis | 1 | 2022 | 50 | 0.170 |
Why?
| | Adolescent | 16 | 2024 | 22428 | 0.170 |
Why?
| | Biomarkers | 4 | 2024 | 4271 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 239 | 0.170 |
Why?
| | Sarcoidosis | 1 | 2023 | 160 | 0.170 |
Why?
| | Immunization | 2 | 2016 | 374 | 0.170 |
Why?
| | Melanoma, Experimental | 2 | 2019 | 108 | 0.170 |
Why?
| | Endothelium, Vascular | 5 | 2019 | 965 | 0.160 |
Why?
| | Severity of Illness Index | 3 | 2024 | 2925 | 0.160 |
Why?
| | Immunomodulation | 1 | 2020 | 101 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 1129 | 0.160 |
Why?
| | Neoplasm Proteins | 3 | 2017 | 442 | 0.150 |
Why?
| | Female | 31 | 2025 | 78271 | 0.150 |
Why?
| | Cellular Reprogramming | 1 | 2020 | 103 | 0.150 |
Why?
| | Keratin-14 | 2 | 2009 | 15 | 0.150 |
Why?
| | Advisory Committees | 1 | 2020 | 228 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 280 | 0.140 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 3 | 2012 | 91 | 0.140 |
Why?
| | Child, Preschool | 12 | 2021 | 11787 | 0.140 |
Why?
| | Cells, Cultured | 14 | 2017 | 4154 | 0.140 |
Why?
| | Interleukin-1beta | 1 | 2020 | 395 | 0.130 |
Why?
| | Ligands | 10 | 2016 | 673 | 0.130 |
Why?
| | Immunoglobulin G | 2 | 2012 | 893 | 0.130 |
Why?
| | Cell Polarity | 2 | 2016 | 137 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 461 | 0.130 |
Why?
| | Candidiasis | 1 | 2017 | 64 | 0.130 |
Why?
| | Candida albicans | 1 | 2017 | 61 | 0.130 |
Why?
| | Kaposi Varicelliform Eruption | 1 | 2017 | 21 | 0.130 |
Why?
| | Lymphadenitis | 1 | 2016 | 6 | 0.130 |
Why?
| | Administration, Cutaneous | 1 | 2017 | 125 | 0.130 |
Why?
| | Hereditary Autoinflammatory Diseases | 1 | 2016 | 13 | 0.130 |
Why?
| | Stomatitis, Aphthous | 1 | 2016 | 9 | 0.130 |
Why?
| | Pharyngitis | 1 | 2016 | 25 | 0.120 |
Why?
| | Interleukin-23 | 1 | 2016 | 16 | 0.120 |
Why?
| | Dermatomyositis | 2 | 2009 | 24 | 0.120 |
Why?
| | Receptors, CCR4 | 3 | 2012 | 23 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2018 | 282 | 0.120 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2017 | 158 | 0.120 |
Why?
| | Interleukins | 2 | 2016 | 248 | 0.120 |
Why?
| | Virus Replication | 2 | 2017 | 529 | 0.110 |
Why?
| | Psoriasis | 3 | 2017 | 112 | 0.110 |
Why?
| | Immune Tolerance | 2 | 2009 | 379 | 0.110 |
Why?
| | Young Adult | 6 | 2024 | 14105 | 0.110 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2015 | 11 | 0.110 |
Why?
| | Dermatitis, Atopic | 2 | 2009 | 321 | 0.110 |
Why?
| | Cell Line | 7 | 2011 | 2882 | 0.110 |
Why?
| | Mice, SCID | 4 | 2020 | 369 | 0.110 |
Why?
| | Neutrophils | 4 | 2012 | 1134 | 0.110 |
Why?
| | Transcriptome | 1 | 2021 | 1045 | 0.110 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 80 | 0.110 |
Why?
| | Granzymes | 1 | 2015 | 49 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2010 | 668 | 0.110 |
Why?
| | Male | 22 | 2024 | 72315 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 276 | 0.100 |
Why?
| | Interleukin-17 | 2 | 2017 | 118 | 0.100 |
Why?
| | HLA-DR Antigens | 1 | 2015 | 220 | 0.100 |
Why?
| | Hyaluronan Receptors | 3 | 2011 | 102 | 0.100 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2015 | 82 | 0.100 |
Why?
| | Neoplasms | 3 | 2020 | 2875 | 0.100 |
Why?
| | Dermatitis, Allergic Contact | 2 | 2011 | 72 | 0.100 |
Why?
| | Receptors, CCR7 | 1 | 2013 | 31 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 2 | 2011 | 420 | 0.100 |
Why?
| | Microscopy | 1 | 2015 | 156 | 0.100 |
Why?
| | Lipid Metabolism | 1 | 2017 | 527 | 0.100 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 21 | 0.090 |
Why?
| | B-Lymphocytes | 4 | 2011 | 876 | 0.090 |
Why?
| | Interleukin-9 | 1 | 2012 | 12 | 0.090 |
Why?
| | CD18 Antigens | 1 | 2012 | 22 | 0.090 |
Why?
| | Biomechanical Phenomena | 2 | 2015 | 842 | 0.090 |
Why?
| | Antigens, Ly | 1 | 2012 | 40 | 0.090 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 104 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2016 | 409 | 0.090 |
Why?
| | Lymphocyte Count | 1 | 2012 | 164 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2012 | 784 | 0.090 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 251 | 0.090 |
Why?
| | Transforming Growth Factors | 1 | 2011 | 3 | 0.090 |
Why?
| | Langerhans Cells | 1 | 2011 | 12 | 0.090 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.080 |
Why?
| | Autoimmune Diseases | 2 | 2007 | 463 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 1720 | 0.080 |
Why?
| | Vaccination | 2 | 2017 | 1423 | 0.080 |
Why?
| | Epidermis | 2 | 2016 | 157 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2015 | 780 | 0.080 |
Why?
| | Inflammation | 6 | 2012 | 2878 | 0.080 |
Why?
| | Antigens, CD | 2 | 2007 | 555 | 0.080 |
Why?
| | Program Development | 1 | 2012 | 370 | 0.080 |
Why?
| | Integrins | 1 | 2010 | 89 | 0.080 |
Why?
| | Fucosyltransferases | 3 | 2018 | 33 | 0.080 |
Why?
| | Mice, Inbred BALB C | 4 | 2018 | 1253 | 0.080 |
Why?
| | Viral Load | 1 | 2012 | 526 | 0.080 |
Why?
| | Flow Cytometry | 6 | 2013 | 1173 | 0.070 |
Why?
| | Receptors, Interleukin-1 | 2 | 2006 | 213 | 0.070 |
Why?
| | Cytokines | 3 | 2007 | 2061 | 0.070 |
Why?
| | Metalloendopeptidases | 4 | 2012 | 62 | 0.070 |
Why?
| | Microtubule-Associated Proteins | 1 | 2010 | 196 | 0.070 |
Why?
| | Hypersensitivity, Delayed | 2 | 2007 | 29 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 7990 | 0.070 |
Why?
| | beta Catenin | 1 | 2011 | 252 | 0.070 |
Why?
| | Lymph Nodes | 4 | 2016 | 502 | 0.070 |
Why?
| | Ovalbumin | 1 | 2009 | 190 | 0.070 |
Why?
| | Shear Strength | 1 | 2009 | 72 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2009 | 2182 | 0.070 |
Why?
| | Arthritis | 2 | 2024 | 96 | 0.070 |
Why?
| | Rheology | 1 | 2009 | 94 | 0.070 |
Why?
| | Joints | 2 | 2024 | 107 | 0.070 |
Why?
| | Toll-Like Receptors | 1 | 2009 | 194 | 0.070 |
Why?
| | Cell Differentiation | 4 | 2025 | 2050 | 0.070 |
Why?
| | Cancer Vaccines | 2 | 2012 | 160 | 0.070 |
Why?
| | Protein Precursors | 1 | 1988 | 137 | 0.070 |
Why?
| | Self Tolerance | 1 | 2007 | 26 | 0.070 |
Why?
| | Vitamin A | 1 | 2007 | 59 | 0.070 |
Why?
| | MART-1 Antigen | 1 | 2007 | 8 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2020 | 3540 | 0.070 |
Why?
| | Toll-Like Receptor 7 | 1 | 2007 | 43 | 0.060 |
Why?
| | Feasibility Studies | 2 | 2024 | 1095 | 0.060 |
Why?
| | Chemokine CCL17 | 2 | 2004 | 5 | 0.060 |
Why?
| | Cholecalciferol | 1 | 2007 | 60 | 0.060 |
Why?
| | CD8 Antigens | 1 | 2007 | 72 | 0.060 |
Why?
| | Drug Therapy, Combination | 3 | 2019 | 1047 | 0.060 |
Why?
| | Receptors, Chemokine | 2 | 2006 | 47 | 0.060 |
Why?
| | Microcirculation | 2 | 2005 | 138 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 2007 | 467 | 0.060 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 186 | 0.060 |
Why?
| | HeLa Cells | 1 | 2008 | 650 | 0.060 |
Why?
| | Polysaccharides | 3 | 2011 | 87 | 0.060 |
Why?
| | Th1 Cells | 1 | 2007 | 139 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2024 | 3604 | 0.060 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 3 | 2010 | 40 | 0.060 |
Why?
| | Up-Regulation | 2 | 2009 | 851 | 0.060 |
Why?
| | Sialoglycoproteins | 1 | 2006 | 158 | 0.060 |
Why?
| | Methylprednisolone | 2 | 2019 | 64 | 0.060 |
Why?
| | Transfection | 1 | 1988 | 940 | 0.060 |
Why?
| | Microscopy, Video | 1 | 2006 | 25 | 0.060 |
Why?
| | Urticaria | 1 | 2006 | 38 | 0.060 |
Why?
| | Neuraminidase | 4 | 2001 | 24 | 0.060 |
Why?
| | Vitamin D | 1 | 2009 | 400 | 0.060 |
Why?
| | Cell Lineage | 1 | 2008 | 376 | 0.060 |
Why?
| | Wiskott-Aldrich Syndrome Protein | 1 | 2005 | 4 | 0.060 |
Why?
| | Viral Vaccines | 1 | 2006 | 107 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1054 | 0.060 |
Why?
| | Bone Marrow Cells | 3 | 2002 | 320 | 0.060 |
Why?
| | Graft vs Host Disease | 1 | 2007 | 264 | 0.060 |
Why?
| | Signal Transduction | 5 | 2025 | 5226 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2006 | 737 | 0.050 |
Why?
| | Immunologic Factors | 1 | 2007 | 255 | 0.050 |
Why?
| | Membrane Proteins | 3 | 1998 | 1166 | 0.050 |
Why?
| | Disease Progression | 3 | 2024 | 2847 | 0.050 |
Why?
| | Th2 Cells | 1 | 2005 | 171 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 846 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1560 | 0.050 |
Why?
| | Neutrophil Activation | 2 | 2012 | 85 | 0.050 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 23 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2004 | 23 | 0.050 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2004 | 49 | 0.050 |
Why?
| | Cell Separation | 3 | 2013 | 307 | 0.050 |
Why?
| | Leukocytosis | 1 | 2003 | 32 | 0.050 |
Why?
| | Adult | 8 | 2024 | 40449 | 0.050 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 17 | 0.050 |
Why?
| | Neoplastic Stem Cells | 1 | 2008 | 412 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 1987 | 863 | 0.050 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2023 | 33 | 0.050 |
Why?
| | Raynaud Disease | 1 | 2003 | 3 | 0.050 |
Why?
| | Fasciitis | 1 | 2023 | 11 | 0.050 |
Why?
| | Neuroglia | 1 | 2024 | 172 | 0.050 |
Why?
| | Coronary Vessels | 1 | 2005 | 251 | 0.050 |
Why?
| | Mice, Inbred NOD | 2 | 2019 | 610 | 0.050 |
Why?
| | Observer Variation | 1 | 2024 | 355 | 0.050 |
Why?
| | Immunocompetence | 2 | 2017 | 47 | 0.050 |
Why?
| | Neutropenia | 1 | 2003 | 155 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2003 | 133 | 0.050 |
Why?
| | DNA | 2 | 1988 | 1463 | 0.050 |
Why?
| | Prednisone | 2 | 2019 | 221 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 416 | 0.050 |
Why?
| | Chemokines, CXC | 2 | 2005 | 68 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 3 | 2012 | 675 | 0.040 |
Why?
| | Syndrome | 2 | 2016 | 380 | 0.040 |
Why?
| | Hemorheology | 2 | 1999 | 24 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2006 | 780 | 0.040 |
Why?
| | B-Lymphocyte Subsets | 1 | 2001 | 80 | 0.040 |
Why?
| | Acute Disease | 2 | 2020 | 1030 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1821 | 0.040 |
Why?
| | Calcinosis | 1 | 2002 | 234 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 548 | 0.040 |
Why?
| | Immunoblotting | 2 | 1998 | 300 | 0.040 |
Why?
| | Registries | 2 | 2020 | 2385 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2020 | 4557 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1716 | 0.040 |
Why?
| | Glycosylation | 2 | 2012 | 172 | 0.040 |
Why?
| | Macrophages | 1 | 1987 | 1511 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 108 | 0.040 |
Why?
| | Integrin beta Chains | 1 | 2018 | 7 | 0.040 |
Why?
| | Lower Extremity | 1 | 2023 | 438 | 0.040 |
Why?
| | Immunophenotyping | 2 | 2015 | 322 | 0.040 |
Why?
| | Remission Induction | 2 | 2010 | 307 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 170 | 0.040 |
Why?
| | Rare Diseases | 1 | 2019 | 113 | 0.040 |
Why?
| | Protein Binding | 3 | 2012 | 2273 | 0.040 |
Why?
| | Calcium | 2 | 2012 | 1183 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 223 | 0.030 |
Why?
| | Interleukin-2 | 2 | 2010 | 437 | 0.030 |
Why?
| | Endothelium, Lymphatic | 1 | 1998 | 11 | 0.030 |
Why?
| | Epitopes | 2 | 1998 | 485 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2020 | 281 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 1997 | 42 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2021 | 6429 | 0.030 |
Why?
| | Antigen-Presenting Cells | 2 | 1989 | 160 | 0.030 |
Why?
| | Allografts | 1 | 2018 | 150 | 0.030 |
Why?
| | Needs Assessment | 1 | 2020 | 404 | 0.030 |
Why?
| | Down-Regulation | 2 | 2012 | 627 | 0.030 |
Why?
| | Oligosaccharides | 1 | 1998 | 60 | 0.030 |
Why?
| | Pain | 1 | 2023 | 779 | 0.030 |
Why?
| | Altitude | 1 | 2021 | 473 | 0.030 |
Why?
| | Familial Mediterranean Fever | 1 | 2016 | 7 | 0.030 |
Why?
| | Turkey | 1 | 2016 | 19 | 0.030 |
Why?
| | Middle Aged | 4 | 2024 | 35875 | 0.030 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1996 | 39 | 0.030 |
Why?
| | Edetic Acid | 1 | 1996 | 47 | 0.030 |
Why?
| | Boston | 1 | 2016 | 92 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 847 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 730 | 0.030 |
Why?
| | Endopeptidases | 1 | 1996 | 82 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2017 | 79 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1997 | 175 | 0.030 |
Why?
| | Chelating Agents | 1 | 1996 | 71 | 0.030 |
Why?
| | Synovial Fluid | 1 | 2016 | 67 | 0.030 |
Why?
| | Antibodies | 2 | 2012 | 401 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2117 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 948 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2017 | 331 | 0.030 |
Why?
| | Lymphocytes | 1 | 1998 | 382 | 0.030 |
Why?
| | Cell Membrane | 3 | 1988 | 706 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2024 | 3409 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 417 | 0.030 |
Why?
| | Chemokines | 1 | 1996 | 218 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 732 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2007 | 97 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2016 | 194 | 0.030 |
Why?
| | Neurons | 1 | 2024 | 1640 | 0.030 |
Why?
| | Dermatitis, Contact | 2 | 2007 | 18 | 0.030 |
Why?
| | Infant | 4 | 2012 | 10034 | 0.030 |
Why?
| | Eosinophils | 1 | 1997 | 316 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2930 | 0.030 |
Why?
| | Glycolipids | 1 | 1995 | 52 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 1997 | 477 | 0.030 |
Why?
| | Antigens | 1 | 2016 | 347 | 0.030 |
Why?
| | Rituximab | 2 | 2007 | 209 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2015 | 173 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1098 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1886 | 0.020 |
Why?
| | Contractile Proteins | 1 | 2012 | 13 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2017 | 1087 | 0.020 |
Why?
| | Treatment Outcome | 4 | 2012 | 11679 | 0.020 |
Why?
| | Filamins | 1 | 2012 | 28 | 0.020 |
Why?
| | Radiation Chimera | 1 | 2012 | 27 | 0.020 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 14 | 0.020 |
Why?
| | Receptors, Leukotriene B4 | 1 | 2012 | 7 | 0.020 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2012 | 16 | 0.020 |
Why?
| | Leukotriene B4 | 1 | 2012 | 37 | 0.020 |
Why?
| | Global Health | 1 | 2016 | 401 | 0.020 |
Why?
| | Receptors, Interleukin | 1 | 2012 | 43 | 0.020 |
Why?
| | Peritoneum | 1 | 2012 | 45 | 0.020 |
Why?
| | Mice, Inbred CBA | 2 | 1989 | 57 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2012 | 106 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2194 | 0.020 |
Why?
| | Local Lymph Node Assay | 1 | 2011 | 1 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | Chemotaxis | 1 | 2012 | 122 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1694 | 0.020 |
Why?
| | Lymphoid Tissue | 2 | 2005 | 80 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1289 | 0.020 |
Why?
| | Genetic Variation | 1 | 2016 | 983 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 2012 | 540 | 0.020 |
Why?
| | Chemokine CXCL12 | 2 | 2005 | 89 | 0.020 |
Why?
| | Biomedical Research | 1 | 2018 | 710 | 0.020 |
Why?
| | Fibroblasts | 2 | 2005 | 1034 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2011 | 67 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 333 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 319 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3671 | 0.020 |
Why?
| | Motor Activity | 1 | 2016 | 721 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2021 | 17066 | 0.020 |
Why?
| | Mast Cells | 1 | 2012 | 146 | 0.020 |
Why?
| | Longitudinal Studies | 2 | 2009 | 2947 | 0.020 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2010 | 47 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4564 | 0.020 |
Why?
| | Blood Circulation | 1 | 2010 | 44 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2011 | 221 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2005 | 1489 | 0.020 |
Why?
| | Diphtheria Toxin | 1 | 2010 | 65 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 750 | 0.020 |
Why?
| | Risk Factors | 2 | 2016 | 10779 | 0.020 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1989 | 51 | 0.020 |
Why?
| | Complement System Proteins | 1 | 2012 | 316 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 1988 | 41 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 1988 | 50 | 0.020 |
Why?
| | Precipitin Tests | 1 | 1988 | 93 | 0.020 |
Why?
| | Incidence | 1 | 2016 | 2879 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2496 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 635 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2010 | 197 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2001 | 331 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 2012 | 337 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2009 | 5408 | 0.020 |
Why?
| | Muscle Weakness | 1 | 2009 | 92 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 126 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 7190 | 0.020 |
Why?
| | Allergens | 1 | 2011 | 384 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2012 | 2155 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 523 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3162 | 0.020 |
Why?
| | Tissue Array Analysis | 1 | 2008 | 50 | 0.020 |
Why?
| | Aged | 2 | 2023 | 25913 | 0.020 |
Why?
| | Immunoassay | 1 | 1988 | 109 | 0.020 |
Why?
| | Stress, Mechanical | 2 | 2001 | 494 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1989 | 206 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1987 | 30 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2008 | 193 | 0.020 |
Why?
| | Cell Compartmentation | 1 | 1987 | 54 | 0.020 |
Why?
| | Plasmids | 1 | 1988 | 379 | 0.020 |
Why?
| | Umbilical Veins | 2 | 1997 | 59 | 0.020 |
Why?
| | Receptors, CCR6 | 1 | 2006 | 4 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 2006 | 64 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2007 | 160 | 0.020 |
Why?
| | Genetic Linkage | 1 | 1987 | 273 | 0.010 |
Why?
| | CD4 Antigens | 1 | 2006 | 139 | 0.010 |
Why?
| | Cell Division | 1 | 2008 | 766 | 0.010 |
Why?
| | Mice, Nude | 1 | 2008 | 682 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1987 | 193 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 423 | 0.010 |
Why?
| | Papilledema | 1 | 2006 | 44 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 2006 | 129 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2010 | 1462 | 0.010 |
Why?
| | Antigens, Viral | 1 | 2006 | 182 | 0.010 |
Why?
| | Proteomics | 1 | 2012 | 1195 | 0.010 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 202 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 2027 | 0.010 |
Why?
| | Dilatation, Pathologic | 1 | 2005 | 62 | 0.010 |
Why?
| | Meningitis | 1 | 2006 | 80 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1988 | 1370 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1782 | 0.010 |
Why?
| | Receptors, CXCR4 | 1 | 2005 | 91 | 0.010 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2006 | 169 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 779 | 0.010 |
Why?
| | Cytoskeletal Proteins | 1 | 2005 | 156 | 0.010 |
Why?
| | Fibronectins | 1 | 2005 | 136 | 0.010 |
Why?
| | Biological Evolution | 1 | 1989 | 488 | 0.010 |
Why?
| | Intellectual Disability | 1 | 2006 | 175 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5868 | 0.010 |
Why?
| | Kinetics | 2 | 1998 | 1627 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2005 | 195 | 0.010 |
Why?
| | Interferon Type I | 1 | 1985 | 145 | 0.010 |
Why?
| | United States | 1 | 2021 | 15966 | 0.010 |
Why?
| | Bronchitis | 1 | 2003 | 33 | 0.010 |
Why?
| | Fever | 1 | 2005 | 311 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2430 | 0.010 |
Why?
| | Actins | 1 | 2005 | 425 | 0.010 |
Why?
| | Chemokine CCL22 | 1 | 2002 | 3 | 0.010 |
Why?
| | Hearing Loss | 1 | 2006 | 247 | 0.010 |
Why?
| | Echocardiography | 1 | 2005 | 652 | 0.010 |
Why?
| | Interphase | 1 | 2001 | 38 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2008 | 1455 | 0.010 |
Why?
| | HL-60 Cells | 1 | 2001 | 29 | 0.010 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2001 | 26 | 0.010 |
Why?
| | Palatine Tonsil | 1 | 2001 | 55 | 0.010 |
Why?
| | K562 Cells | 1 | 2001 | 93 | 0.010 |
Why?
| | Sinusitis | 1 | 2003 | 228 | 0.010 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2001 | 134 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 2001 | 284 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 402 | 0.010 |
Why?
| | Oxazolone | 1 | 1999 | 5 | 0.010 |
Why?
| | Immunomagnetic Separation | 1 | 1999 | 4 | 0.010 |
Why?
| | Blood Cells | 1 | 1999 | 37 | 0.010 |
Why?
| | Ear, External | 1 | 1999 | 21 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1987 | 2832 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2009 | 1795 | 0.010 |
Why?
| | Carbohydrate Metabolism | 1 | 1998 | 60 | 0.010 |
Why?
| | Endothelium | 1 | 1999 | 119 | 0.010 |
Why?
| | Carbohydrates | 1 | 1998 | 66 | 0.010 |
Why?
| | Diffusion Chambers, Culture | 1 | 1997 | 9 | 0.010 |
Why?
| | Chemotactic Factors, Eosinophil | 1 | 1997 | 7 | 0.010 |
Why?
| | Integrin alpha4 | 1 | 1997 | 7 | 0.010 |
Why?
| | Chemokine CCL11 | 1 | 1997 | 25 | 0.010 |
Why?
| | Antigens, Surface | 1 | 1998 | 157 | 0.010 |
Why?
| | Protein Conformation | 1 | 2000 | 946 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2001 | 699 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2010 | 8265 | 0.010 |
Why?
| | Chymotrypsin | 1 | 1996 | 23 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1998 | 1047 | 0.010 |
Why?
| | Chemokine CCL2 | 1 | 1996 | 115 | 0.010 |
Why?
| | Time Factors | 1 | 1987 | 7173 | 0.010 |
Why?
| | Carbohydrate Sequence | 1 | 1995 | 28 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 4089 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1996 | 594 | 0.010 |
Why?
| | Prognosis | 1 | 2002 | 4282 | 0.010 |
Why?
| | Phylogeny | 1 | 1996 | 1016 | 0.010 |
Why?
| | Cell Fractionation | 1 | 1989 | 52 | 0.000 |
Why?
| | Lymphokines | 1 | 1989 | 130 | 0.000 |
Why?
| | Nucleic Acid Hybridization | 1 | 1989 | 187 | 0.000 |
Why?
| | Mice, Inbred C3H | 1 | 1989 | 251 | 0.000 |
Why?
| | Culture Media | 1 | 1989 | 161 | 0.000 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1989 | 131 | 0.000 |
Why?
| | Drug Combinations | 1 | 1989 | 390 | 0.000 |
Why?
| | Hybrid Cells | 1 | 1987 | 49 | 0.000 |
Why?
| | Spleen | 1 | 1989 | 508 | 0.000 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1987 | 64 | 0.000 |
Why?
| | Genetic Markers | 1 | 1987 | 331 | 0.000 |
Why?
| | Recombination, Genetic | 1 | 1987 | 205 | 0.000 |
Why?
| | Chromosome Mapping | 1 | 1987 | 510 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1985 | 223 | 0.000 |
Why?
| | Peptides | 1 | 1987 | 995 | 0.000 |
Why?
| | Immunotherapy | 1 | 1985 | 653 | 0.000 |
Why?
|
|
Fuhlbrigge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|